Should I Buy RXRX? RXRX 2026 Analysis

Should You Buy Recursion Pharmaceuticals Inc (RXRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.320

1 Day change

-3.36%

52 Week Range

12.360

Analysis Updated At

2026/01/26

Recursion Pharmaceuticals Inc (RXRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline, the financial performance is weak, and the technical indicators do not suggest a compelling entry point. Additionally, there are no strong trading signals or recent positive news to act as a catalyst for immediate growth.

Technical Analysis

The MACD is slightly positive (0.0278) but contracting, indicating weakening momentum. RSI is neutral at 53.102, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (4.764), with resistance at 5.104 and support at 4.424. Overall, the technical indicators suggest a lack of strong directional movement.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment among options traders, but the implied volatility (97.26) and historical volatility (107.03) suggest high risk and uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

These developments highlight potential long-term growth opportunities.

Neutral/Negative Catalysts

The company's financial performance is weak, with revenue dropping by 80.16% YoY and gross margin significantly deteriorating (-183.81). Additionally, the stock has a 60% probability of declining over the next day (-0.58%), week (-4.43%), and month (-10.83%), based on historical patterns.

Financial Performance

In Q3 2025, revenue dropped significantly (-80.16% YoY) to $5.18M. Net income improved but remains negative at -$162.25M (+69.29% YoY). EPS increased slightly to -0.36 (+5.88% YoY). Gross margin worsened drastically to -183.81 (-442.35% YoY), reflecting operational inefficiencies.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

JPMorgan upgraded RXRX to Overweight from Neutral with a price target increase from $10 to $11. The analyst cited strong efficacy of REC-4881 and promising early results for REC-617, with a broader addressable market and blockbuster potential.

6 Analyst Rating

Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 7.75 USD with a low forecast of 5 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

4 Hold

0 Sell

Moderate Buy

Current: 4.470

Low

Averages

7.75

High

Current: 4.470

Low

Averages

7.75

High

JPMorgan

Neutral -> Overweight

upgrade

$10 -> $11

AI Analysis

2025-12-17

Reason

JPMorgan

Price Target

$10 -> $11

AI Analysis

2025-12-17

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Recursion Pharmaceuticals to Overweight from Neutral with a price target of $11, up from $10. The firm says the company's REC-4881 has shown "strong and durable" efficacy in familial adenomatous polyposis. REC-4881's addressable market is now broader than previously expected, creating blockbuster potential, the analyst tells investors in a research note. JPMorgan sees peak sales of over $1B and a 60% probability of success. In addition, Recursion's REC-617, a CDK7 inhibitor, has shown early anti-tumor activity in platinum-resistant ovarian cancer, says JPMorgan.

Morgan Stanley

Equal Weight

initiated

2025-07-03

Reason

Morgan Stanley

Price Target

2025-07-03

initiated

Equal Weight

Reason

Morgan Stanley assumed coverage of Recursion Pharmaceuticals with an Equal Weight rating and $5 price target. Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RXRX

Unlock Now

RXRX Should I Buy

RXRX Should I Buy

Should You Buy Recursion Pharmaceuticals Inc (RXRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch